MRKR Marker Therapeutics, Inc.

CIK 0001094038 50 ready 8-Ks latest May 4, 2026, 7:59 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline Risk accumulating: auditor change (2)

Ready 8-Ks 50

Latest filing May 4, 2026, 7:59 PM ET

Top materiality 0.80

Event mix other_material ×27 · earnings ×10 · leadership ×6

Sentiment 23 pos · 3 neg · 24 neu

Latest earnings reported 2025-Q3

Executive change recent →

SHENANIGAN SCORE 1 / 7 see the board

Recent 8-K filings for MRKR

Highest-materiality recent filing

Marker Therapeutics: 78% objective response in APOLLO study; raises $16.1M in private placement

December 19, 2024, 6:59 PM ET other material materiality 0.80 positive item 1.01 item 8.01 item 9.01

Phase 1 APOLLO: 78% of patients (7/9) achieved objective response; 44.4% complete response at first assessment.
MT-601 well tolerated; no ICANS observed, one Grade 1 CRS; no dose-limiting toxicities.

Read filing →

May 4, 2026, 7:59 PM ET other material materiality 0.75 neutral item 5.03 item 5.07 item 9.01 ◈ Shareholder Votes ×6◈ Governance Changes

Marker Therapeutics shareholders approve increase in authorized shares from 30M to 130M

Shareholders approved Charter Amendment to increase authorized common stock from 30M to 130M shares (10.9M for, 1.4M against).
November 14, 2025, 6:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01

Marker Therapeutics reports Q3 net loss $2.0M; APOLLO study shows 66% ORR, 50% CR in NHL

Cash $17.6M + restricted $1.4M; runway into Q3 2026; raised ~$10M via ATM.
August 26, 2025, 7:59 PM ET other material materiality 0.70 positive item 7.01 item 9.01

Marker Therapeutics Phase 1 APOLLO data: 66% ORR in NHL; 50% CR; dose expansion cleared

66% objective response rate in NHL patients (8/12), with 50% complete response (6/12) at doses 100-200×10^6 cells.
June 17, 2025, 7:59 PM ET other material materiality 0.70 positive item 1.01 item 8.01 item 9.01

Marker partners Cellipont for cGMP manufacturing of MT-601 for lymphoma trial

Partnered with Cellipont Bioservices for cGMP manufacturing of MT-601, a MAR-T cell therapy for lymphoma in Phase 1 APOLLO study.
May 20, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Marker Therapeutics: lymphodepletion improves MT-601 cell expansion; enrollment surging

Phase 1 APOLLO study data: TCR sequencing shows MT-601 clones expanded/persisted at higher levels with lymphodepletion.
March 31, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Marker Therapeutics FY2024 net loss $10.7M; MT-601 78% response rate in lymphoma

Net loss of $10.7M for FY2024 vs $8.2M in FY2023; R&D expense $13.5M, G&A $4.2M.
December 23, 2024, 6:59 PM ET other material materiality 0.75 neutral item 1.01 item 3.02 item 9.01

Marker Therapeutics closes $16.1M private placement of stock and warrants

Gross proceeds ~$16.1M from sale of 1,783,805 shares, Series A warrants (5,031,250 shares at $4.00/sh), and pre-funded warrants (3,248,445 shares at $0.001/sh).
December 19, 2024, 6:59 PM ET other material materiality 0.80 positive item 1.01 item 8.01 item 9.01

Marker Therapeutics: 78% objective response in APOLLO study; raises $16.1M in private placement

Phase 1 APOLLO: 78% of patients (7/9) achieved objective response; 44.4% complete response at first assessment.
December 17, 2024, 6:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Marker Therapeutics awarded $9.5M CPRIT grant for MT-601 in pancreatic cancer study

Received $9.5M non-dilutive grant from CPRIT to support Phase 1 PANACEA study of MT-601 in metastatic pancreatic cancer.
November 14, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Marker Therapeutics reports Q3 2024 net loss of $2.3M; receives $4M NIH grants

Cash and cash equivalents of $9.0M as of Sept 30, 2024; expects to fund operations into October 2025.
August 14, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Marker Therapeutics Q2 net loss narrows to $2.2M; reports positive MT-601 APOLLO data, receives $2M NIH grant

Net loss from continuing ops $2.2M vs $4.1M YoY; cash $7.8M expected to fund into Q4 2025.
August 12, 2024, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Marker Therapeutics awarded $2M NIH SBIR grant for MT-601 Phase 1 in CAR-relapsed NHL

Awarded $2 million non-dilutive grant from NIH SBIR to support Phase 1 APOLLO study of MT-601 in NHL patients relapsed after anti-CD19 CAR T therapy.
May 15, 2024, 7:59 PM ET other material materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Marker Q1 net loss narrows to $2.4M; MT-601 shows durable CRs in APOLLO trial

Net loss of $2.4M in Q1 2024 vs $4.9M in Q1 2023; cash $11.3M expected to fund into Q4 2025.
April 8, 2024, 7:59 PM ET other material materiality 0.70 positive item 8.01 item 9.01

Marker Therapeutics: MT-601 shows durable CR in lymphoma patient 9 months post-CAR T failure; 3/3 objective responses

First APOLLO participant with DLBCL who relapsed after CAR T remains in complete response 9 months after MT-601 treatment.
March 26, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Marker Therapeutics reports FY 2023 net loss of $8.2M, down from $29.9M; cash runway into Q4 2025

Net loss narrowed to $8.2M in FY 2023 from $29.9M in FY 2022; R&D spend cut to $10.4M from $12.0M.
March 1, 2024, 6:59 PM ET other material materiality 0.60 neutral item 1.02 item 9.01 ◈ Material Agreements

Marker Therapeutics terminates $25M equity purchase agreement with Lincoln Park Capital

Terminated Purchase Agreement with Lincoln Park Capital Fund effective March 1, 2024.
January 8, 2024, 6:59 PM ET other material materiality 0.75 neutral item 7.01 item 9.01

Marker Therapeutics prioritizes MT-601 for CAR T-relapsed lymphoma, discontinues patient-specific AML program

MT-601 for DLBCL patients who relapsed after CAR T: first APOLLO participant maintained complete response at 6 months.
December 11, 2023, 6:59 PM ET other material materiality 0.70 positive item 8.01 item 9.01

Marker Therapeutics reports sustained complete response in Phase 1 lymphoma patient at 6 months

DLBCL patient who failed anti-CD19 CAR T and 3 prior therapies achieved CR at 8 weeks and remains in CR at 6 months after MT-601.
November 20, 2023, 6:59 PM ET leadership materiality 0.60 negative item 5.02 ◈ executive_change ×2

Marker Therapeutics terminates Interim CFO; CEO assumes principal financial officer role

On Nov 17, 2023, Marker terminated Danforth Advisors consulting agreement, effective Jan 16, 2024.
November 9, 2023, 6:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01 ◈ Earnings Releases

Marker Therapeutics reports Q3 net loss $3.0M; complete response in first MT-601 lymphoma patient

Net loss of $3.0M for Q3 2023 vs $6.9M in Q3 2022; R&D expenses down to $2.0M from $3.6M.
September 11, 2023, 7:59 PM ET other material materiality 0.60 positive item 8.01 item 9.01

Marker Therapeutics reports complete response in first lymphoma patient treated with MT-601 after CAR T relapse

First APOLLO trial patient with DLBCL, after 4 prior therapies including CAR T, achieved complete metabolic response at 8 weeks post 2nd MT-601 infusion.
August 14, 2023, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

Marker Therapeutics Q2 net income $2.5M; Cell Ready deal extends cash runway into Q4 2025

Net income of $2.5M vs net loss of $9.2M in Q2 2022; cash and equivalents $18.1M.
August 7, 2023, 7:59 PM ET other material materiality 0.60 positive item 7.01 item 9.01

Marker Therapeutics reports non-clinical proof-of-concept data for MT-401 OTS, expects first patient treatment H1 2024

Non-clinical data: MT-401 OTS killed AML cells in vitro with 2/8 HLA match, significantly reducing THP-1 cell growth.
July 10, 2023, 7:59 PM ET regulatory materiality 0.65 positive item 7.01 item 9.01

Marker Therapeutics' MT-401 receives EMA Orphan Drug Designation for AML

EMA granted Orphan Drug Designation for zedenoleucel (MT-401) for acute myeloid leukemia (AML).
June 30, 2023, 7:59 PM ET M&A materiality 0.80 neutral item 2.01 item 9.01 ◈ M&A Transactions

Marker Therapeutics completes $19M sale of manufacturing facilities to Cell Ready, exits manufacturing operations

Completed disposition of manufacturing facilities and equipment to Cell Ready for $19M on June 26, 2023.
June 26, 2023, 7:59 PM ET other material materiality 0.65 positive item 7.01 item 9.01

Marker Therapeutics reports non-clinical data showing MT-401 + HMA synergy; awarded $2M NIH grant

Non-clinical in vitro data: MT-401 after HMA (5'-Azacytidine) significantly decreased AML THP-1 cell growth vs. either agent alone, suggesting synergy.
June 12, 2023, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 9.01

Marker Therapeutics treats first lymphoma patient in Phase 1 APOLLO trial of MT-601

First patient dosed at 200 million cells; no treatment-related adverse events after 18 days.
May 31, 2023, 7:59 PM ET other material materiality 0.70 positive item 7.01 item 9.01

Marker Therapeutics reports pre-clinical data showing MT-601 kills CD19 CAR T refractory lymphoma cells

In vitro, MT-601 completely inhibited growth of lymphoma cells resistant to CD19 CAR T therapy after 3 weeks.
May 8, 2023, 7:59 PM ET leadership materiality 0.65 positive item 7.01 item 9.01

Marker Therapeutics names Monic Stuart, M.D., as new CMO; she brings 20+ years drug development experience

Dr. Stuart appointed CMO effective May 8, 2023; will oversee multiTAA-specific T cell pipeline including MT-401 Phase 2 ARTEMIS study.
May 1, 2023, 7:59 PM ET M&A materiality 0.75 positive item 1.01 item 5.02 item 7.01 item 9.01 ◈ executive_change ×4◈ Material Agreements

Marker Therapeutics sells manufacturing assets for $19M, appoints Juan Vera as CEO, extends runway to end of 2025

CellReady to purchase Marker's manufacturing assets for ~$19M in cash; annual overhead reduced by ~$11M; closing targeted June 26, 2023.
March 22, 2023, 7:59 PM ET earnings materiality 0.65 negative item 2.02 item 9.01

Marker Therapeutics reports FY2022 net loss of $29.9M; cash runs into Q3 2023; suspends frank relapse enrollment

Net loss $29.9M for FY2022, improved from $41.9M in prior year.
March 16, 2023, 7:59 PM ET leadership materiality 0.60 negative item 5.02 ◈ executive_change

Chief Medical Officer Mythili Koneru resigns effective April 9, 2023

Mythili Koneru notified Marker Therapeutics of her resignation as Chief Medical Officer, effective April 9, 2023.
December 13, 2022, 6:59 PM ET other material materiality 0.60 neutral item 1.01 item 3.02 item 7.01 item 9.01 ◈ Material Agreements ×2

Marker Therapeutics enters $25M common stock purchase agreement with Lincoln Park Capital

Up to $25M in common stock may be sold to Lincoln Park over 24 months at Marker's discretion.
November 22, 2022, 6:59 PM ET regulatory materiality 0.60 positive item 7.01 item 9.01

FDA clears Marker Therapeutics IND for MT-601 to treat pancreatic cancer

FDA cleared IND for MT-601, a six-antigen T cell therapy for locally advanced unresectable or metastatic pancreatic cancer.
November 10, 2022, 6:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01 ◈ Earnings Releases

Marker Therapeutics Q3 net loss narrows to $6.9M; FDA grant awarded for AML trial

Net loss of $6.9M in Q3 2022, compared to $12.4M loss in Q3 2021.